Novo Nordisk A/S (ADR) (NYSE:NVO)

CAPS Rating: 5 out of 5

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.

Results 1 - 20 of 100 : 1 2 3 4 5 Next »

Recs

0
Member Avatar TMFbuild (47.51) Submitted: 10/9/2014 12:24:07 PM : Outperform Start Price: $44.70 NVO Score: +1.68

I wrote an article on why I like Novo Nordisk -

http://www.fool.com/investing/general/2014/09/25/why-novo-nordisk-stock-is-better-than-the-best.aspx?source=itxsitmot0000001&lidx=2

Recs

0
Member Avatar statman33 (< 20) Submitted: 9/10/2014 11:10:30 PM : Outperform Start Price: $46.38 NVO Score: +0.98

Diabetes treatment is key to health in the future. Well run.

Recs

0
Member Avatar WesKirk (48.48) Submitted: 7/2/2014 5:18:35 AM : Outperform Start Price: $46.29 NVO Score: +0.10

Basically, diabetes care and management has begun to significantly improve, as the cure for diabetes is closer and closer in sight. Unlike some of the other competitition, this company has medicine that doesn't require massive FDA testing and issues during such, and I feel its going to be a force to be reckoned with down the line.

Recs

0
Member Avatar knockripper (39.52) Submitted: 6/23/2014 2:14:14 PM : Outperform Start Price: $45.92 NVO Score: +0.25

biotech is future!!!!!!

Recs

0
Member Avatar invbrow (< 20) Submitted: 6/14/2014 10:59:12 AM : Outperform Start Price: $45.56 NVO Score: +0.07

Favorable FDA Ruling on Victoza for obesity indication in September will bring new Rx's for an existing product.

Recs

0
Member Avatar aymo0003 (< 20) Submitted: 5/1/2014 11:00:51 PM : Outperform Start Price: $44.34 NVO Score: -0.13

1. Market leader in a growing industry
2. Excellent management
3. Fundamentals
4. Profitable growth
5. Diabetes

Recs

0
Member Avatar afewgoodstocks11 (24.65) Submitted: 3/22/2014 12:02:00 AM : Outperform Start Price: $32.25 NVO Score: +16.40

The stock NVO has paid out a dividend of $0.61245. NVO seems to pay dividend once a year. Caps has the wrong div on the stock page, even though i got the alert.

Div. (Yield) $0.61 (1.389%)
Current Yield . . . . . . . 1.89%

Recs

0
Member Avatar NHWeston102 (62.96) Submitted: 3/14/2014 1:09:49 PM : Outperform Start Price: $45.06 NVO Score: -3.41

"The fox knows many things; the hedgehog knows but one thing - but knows it really, really, really well !" NVO is the hedgehog of diabetes treatment and, while diabetes is a global epidemic, not all comers will win permanent market share. NVO will...and will dominate besides.

Recs

0
Member Avatar Beginner110 (79.06) Submitted: 1/18/2014 2:13:00 PM : Outperform Start Price: $37.78 NVO Score: +15.27

Based on past performance and economic outlook I expect this to at least double in next 4 years. With consistent stock price and earnings growth this exciting.

Recs

0
Member Avatar danyariv (< 20) Submitted: 1/11/2014 5:13:07 PM : Outperform Start Price: $38.29 NVO Score: +13.14

diabetes is an epidemy, daily new people are discovered

Recs

0
Member Avatar Sagetology (47.15) Submitted: 12/27/2013 11:36:41 PM : Outperform Start Price: $36.21 NVO Score: +19.91

Competitors are facing patent expiry. The world is experiencing a growing need for diabetes treatment.

Recs

1
Member Avatar Stockllama10 (57.17) Submitted: 12/24/2013 6:33:07 PM : Outperform Start Price: $35.59 NVO Score: +21.75

1.) The P/E, P/B, P/CF, and P/S might not be pretty, but compare that to the overall industry and the concerns vanish. Especially with a fair value picked from $210 by Seeking Alpha and $222 by Morningstar.

2.) A solid moat with a large portfolio of successful drugs, although Tresiba might not be released to the U.S until past 2017, giving Sanofi some time to chip away. But...

3.) A Morningstar Stewardship Grade of "Exemplary". They were also ranked among the most innovative companies by Forbes magazine. As it is stated in Walter Issacson's biography of Steve Jobs: "The mark of an innovative company is not only that it comes up with new ideas first. It also knows how to leapfrog when it finds itself behind." If only one company has the right leadership in this, it's Novo. Not convinced they're good enough? Try a 94% approval rating of the CEO on Glassdoor.

Recs

0
Member Avatar oldfart65 (36.03) Submitted: 10/21/2013 11:45:07 AM : Outperform Start Price: $34.45 NVO Score: +20.48

Danish company which dominates the diabetes mkt (49% of mkt). 371m people have diabetes. Just announced stk buyback program. Worldwide exposure. Significant growth and high returns. 1.8% dividend. ADR but followed in US

Recs

1
Member Avatar grankh (79.33) Submitted: 10/18/2013 5:38:09 PM : Outperform Start Price: $9.18 NVO Score: +245.57

Still like this stock after all these years, and own it in real life.

Sales have been growing at 10% per year, with earnings growing at 22% per year. The profit margin has been expanding recently, as has the earned-on-equity. Also, I show that last year they had NO DEBT, (which I like a lot). The P/E ratio is above average for this stock, and the PEG ratio is a little high, so the stock is priced higher than it has been in the past, but I think it is worth it for the growth it has shown. It pays a small dividend, (around 1.5%). I am looking for this stock to more than double in the next 5 years, which, with the small dividend, could give me an almost 20% per year gain on this stock. Not too shabby, if expectations become reality.

Recs

0
Member Avatar vinney11 (87.11) Submitted: 8/7/2013 12:02:43 PM : Outperform Start Price: $34.10 NVO Score: +18.36

The fatter we get the more money they make!

Recs

0
Member Avatar JHoop (< 20) Submitted: 5/29/2013 9:49:01 PM : Outperform Start Price: $32.70 NVO Score: +21.56

diabetes is a growth disease

Recs

0
Member Avatar Teacherman333 (67.70) Submitted: 5/15/2013 1:51:41 PM : Outperform Start Price: $34.01 NVO Score: +14.83

For reference point and to allow for comments by others. As of the end of March, 2013.

ROE 68.77%
Trailing PE 24.36
PB 16.13
Div yield 1.30%

Recs

0
Member Avatar jesleahfriliv (69.92) Submitted: 4/27/2013 4:30:04 PM : Outperform Start Price: $34.47 NVO Score: +9.78

Very big pipeline ón the Way to US

Recs

0
Member Avatar JMacSol (71.75) Submitted: 3/12/2013 1:45:51 PM : Outperform Start Price: $34.10 NVO Score: +8.76

Bullish on long-term need for diabetes treatment and care. Fundamentals solid and sustainable for current premium valuation.

Recs

0
Member Avatar monsterrabbit (< 20) Submitted: 3/10/2013 3:23:56 PM : Outperform Start Price: $34.15 NVO Score: +8.45

World leader in insulin and diabetes products, well-run company, expanding into emerging markets as disease spreads through the newly affluent world.

Results 1 - 20 of 100 : 1 2 3 4 5 Next »

Featured Broker Partners


Advertisement